Patents by Inventor Diane Hahn

Diane Hahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidinone derivatives as MetAP-2 inhibitors
    Patent number: 10005756
    Abstract: Compounds according to Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 26, 2018
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Frank Zenke, Felix Rohdich, Manja Friese-Hamim, Diane Hahn
  • PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS
    Publication number: 20170226080
    Abstract: Compounds according to Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: July 10, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Timo HEINRICH, Frank ZENKE, Felix ROHDICH, Manja FRIESE-HAMIM, Diane HAHN
  • Engineered anti-alpha V-integrin hybrid antibodies
    Patent number: 8562986
    Abstract: The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: October 22, 2013
    Assignee: Merck Patent GmbH
    Inventors: Simon Goodman, Diane Hahn, Francesc Mitjans, Jaume Adan, Kin-Ming Lo
  • ENGINEERED ANTI-ALPHA V-INTEGRIN HYBRID ANTIBODIES
    Publication number: 20100254977
    Abstract: The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
    Type: Application
    Filed: July 17, 2008
    Publication date: October 7, 2010
    Applicant: MERCK PATENT GMBH
    Inventors: Simon Goodman, Diane Hahn, Francesc Mitjans, Jaume Adan, Kin-Ming Lo
  • Anti-.alpha.V-integrin monoclonal antibody
    Patent number: 5985278
    Abstract: The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:reacting only with the .alpha.V-chain of human .alpha.V-integrins,blocking the attachment to the integrin substrate of the .alpha.V-integrin bearing cell,triggering reversal of established cell matrix interaction caused by .alpha.V-integrins,blocking tumor development, andshowing no cytotoxic activity.
    Type: Grant
    Filed: December 19, 1995
    Date of Patent: November 16, 1999
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Francesc Mitjans, Jaume Piulats, Elisabet Rosell, Jaume Adan, Simon Goodman, Diane Hahn